ORCID as entered in ROS
https://orcid.org/0000-0002-4257-7620
Select Publications
Conference Papers
, 2022, 'Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2617 - 2617
, 2022, 'Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 1053 - 1053
, 2022, 'Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2621 - 2621
, 2022, 'Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 673 - 674
, 2022, 'Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 33 - 34
, 2022, 'Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 116 - 116
, 2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 297 - 298
, 2022, 'On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 631 - 631
, 2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2647 - 2647, http://dx.doi.org/10.26190/unsworks/28409
, 2021, 'Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial', in ARTHRITIS & RHEUMATOLOGY, WILEY, pp. 1372 - 1373, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000744545202187&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2021, 'ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, presented at
, 2021, 'Sglt2 inhibition for ckd and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation', in Diabetes, pp. 1 - 16, http://dx.doi.org/10.2337/dbi20-0040
, 2021, 'ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B2 - B3
, 2021, 'Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 47 - 47
, 2021, 'Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 263 - 264
, 2021, 'IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 190 - 190
, 2021, 'The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 728 - 728
, 2021, 'The TESTING Study: Steroids vs. Placebo in High Risk IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B1 - B1
, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE KIDNEY FUNCTION: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Renoprotection with semaglutide and liraglutide: Direct or indirect effects?', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, pp. S67 - S68, presented at
, 2020, 'Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop', in American Journal of Kidney Diseases, pp. 109 - 120, http://dx.doi.org/10.1053/j.ajkd.2020.01.022
, 2020, 'EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, pp. 152 - 152, presented at
, 2020, 'REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, pp. 183 - 183, presented at
, 2020, 'Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency', in American Journal of Kidney Diseases, pp. 84 - 104, http://dx.doi.org/10.1053/j.ajkd.2019.06.009
, 2019, 'Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial', in DIABETES-METABOLISM RESEARCH AND REVIEWS, WILEY, PEOPLES R CHINA, Xiamen, presented at
, 2019, 'Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, PA, Philadelphia, presented at
, 2019, 'First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, FRANCE, Paris, pp. 3877 - 3877, presented at
, 2018, 'Effects of the DPP-4 Inhibitor Linagliptin on Heart Failure Outcomes in Patients With Type 2 Diabetes and Cardio-Renal Disease in CARMELINA', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, pp. E771 - E772, presented at
, 2018, 'Canagliflozin and cardiovascular outcomes in patients with chronic kidney disease', in DIABETOLOGIA, SPRINGER, GERMANY, Berlin, pp. S39 - S39, presented at
, 2018, 'Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes-The ADVANCE Trial', in DIABETES, AMER DIABETES ASSOC, FL, Orlando, presented at
, 2017, 'Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, CA, Anaheim, pp. E454 - E455, presented at
, 2017, 'CARMELINA® trial baseline characteristics: a cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk', in DIABETOLOGIA, SPRINGER, PORTUGAL, Lisbon, pp. S357 - S357, presented at
, 2017, 'CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk', in DIABETES, AMER DIABETES ASSOC, CA, San Diego, pp. A344 - A344, presented at
, 2017, 'EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, pp. 12 - 12
, 2017, 'EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS
, 2016, 'Canagliflozin slows progression of renal function decline independent of glycaemic effects', in DIABETOLOGIA, SPRINGER, GERMANY, Munich, pp. S28 - S28, presented at
, 2016, 'Effects of linagliptin on glycaemic control and albuminuria in type 2 diabetes: the MARLINA-T2D™ trial', in DIABETOLOGIA, SPRINGER, GERMANY, Munich, pp. S360 - S360, presented at
, 2016, 'Haemodynamic effects of combination therapy with the DPP-4 inhibitor linagliptin and renin-angiotensin system inhibitors in patients with type 2 diabetes', in DIABETOLOGIA, SPRINGER, GERMANY, Munich, pp. S366 - S367, presented at
, 2016, 'Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease—Improving Global Outcomes (KDIGO) Controversies Conference', in Kidney International, Paris, France, pp. 297 - 305, presented at
, 2016, 'IS IMMUNOSUPPRESSIVE THERAPY BENEFICIAL FOR IDIOPATHIC MEMBRANOUS NEPHROPATHY: A SYSTEMATIC REVIEW AND TRIAL SEQUENTIAL ANALYSIS OF PUBLISHED TRIALS', in NEPHROLOGY, WILEY-BLACKWELL, pp. 112 - 112, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383590600156&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2016, 'TRENDS IN HAEMOGLOBIN CONCENTRATION AND ERYTHROPOIESIS STIMULATING AGENT (ESA) USE IN THE AUSTRALIAN DIALYSIS POPULATION', in NEPHROLOGY, WILEY-BLACKWELL, pp. 119 - 120, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383590600171&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2016, 'TRENDS IN THE RELATIVE SURVIVAL OF MIDDLE AGED AND OLDER PEOPLE ON DIALYSIS IN AUSTRALIA', in NEPHROLOGY, WILEY-BLACKWELL, pp. 98 - 98, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000383590600126&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2016, 'Canagliflozin (CANA) Slows Progression of Renal Function Decline Independent of Glycemic Effects', in DIABETES, AMER DIABETES ASSOC, LA, New Orleans, pp. A18 - A18, presented at
, 2016, 'EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES IN PEOPLE UNDERGOING INVASIVE PROCEDURES: A SYSTEMATIC REVIEW AND METAANALYSIS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, AUSTRIA, Vienna, pp. 413 - 413, presented at
, 2016, 'EFFECTS OF LINAGLIPTIN ON GLYCAEMIC CONTROL AND ALBUMINURIA IN TYPE 2 DIABETES - THE MARLINA-T2D™ TRIAL', in NEPHROLOGY, WILEY-BLACKWELL, pp. 60 - 60
, 2015, 'EFFECTS OF THE MEDITERRANEAN DIET ON CARDIOVASCULAR OUTCOMES: A SYSTEMATIC REVIEW AND META-ANALYSIS', in JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER SCIENCE INC, CA, San Diego, pp. A1448 - A1448, presented at
, 2015, 'THE REGISTRATION OF RANDOMISED TRIALS IN NEPHROLOGY: AN INTERNATIONAL REVIEW', in NEPHROLOGY, WILEY-BLACKWELL, pp. 28 - 29
, 2014, 'DIETARY SODIUM REDUCTION REDUCED ALBUMINURIA IN 1,903 RURAL CHINESE: A CLUSTER RANDOMISED TRIAL', in NEPHROLOGY, WILEY-BLACKWELL, pp. 28 - 28, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339715700044&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'RESEARCH PRIORITIES IN CHRONIC KIDNEY DISEASE: A PRIORITY SETTING PARTNERSHIP', in NEPHROLOGY, WILEY-BLACKWELL, pp. 52 - 52, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339715700132&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2014, 'Long-term Efficacy and Safety of Linagliptin in Type 2 Diabetes Patients with Moderate to Severe Renal Disease', in DIABETES, AMER DIABETES ASSOC, pp. A264 - A264, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359481601352&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
Filter by type
https://orcid.org/0000-0002-4257-7620